BOLT biotech catalysts & pipeline

BDC-4182 — Initial data

Q3 2026

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results